-transparent.png){kind=logo}
Amikacin was used in the treatment of 56 serious gram-negative infections in 54 patients of whom 47 survived. In six of the seven nonsurvivors, the infections were under control at the time of death. The clinical isolates were multiple drug-resistant gram-negative organisms, with Proteus rettgeri being most common. Forty-five (80%) of these infections were nosocomial in origin, and the genitourinary tract was the source in 39 (70%). Complications directly related to amikacin therapy were few and suggested renal or otologic toxicity. In this series of patients, amikacin appeared to be of therapeutic benefit in the treatment of serious gram-negative infections.
Related Publications
S C Doughty, and
R R Martin, and
S B Greenberg
July 1979,
Medizinische Klinik,
S C Doughty, and
R R Martin, and
S B Greenberg
January 1993,
Polski tygodnik lekarski (Warsaw, Poland : 1960),
S C Doughty, and
R R Martin, and
S B Greenberg
November 1976,
The Journal of infectious diseases,
S C Doughty, and
R R Martin, and
S B Greenberg
July 1985,
The American journal of medicine,
S C Doughty, and
R R Martin, and
S B Greenberg
September 1986,
Diagnostic microbiology and infectious disease,
S C Doughty, and
R R Martin, and
S B Greenberg
April 1974,
The Japanese journal of antibiotics,
S C Doughty, and
R R Martin, and
S B Greenberg
November 1976,
The Journal of infectious diseases,
S C Doughty, and
R R Martin, and
S B Greenberg
May 1974,
Antimicrobial agents and chemotherapy,
S C Doughty, and
R R Martin, and
S B Greenberg
January 1989,
La Clinica terapeutica,
S C Doughty, and
R R Martin, and
S B Greenberg
August 1977,
Urology,
